Bioxcel Therapeutics Restructures Credit and Strengthens Leadership

Bioxcel Therapeutics ( (BTAI) ) has provided an announcement.

BioXcel Therapeutics has restructured its credit agreement, introducing new capital-raising requirements while modifying liquidity covenants and interest rates. The company must raise specific funds by set dates and will issue new warrants as part of the agreement. Additionally, David Mack joins the board, bringing extensive legal and strategic experience, and a new patent has been listed in the FDA’s Orange Book, potentially enhancing the company’s intellectual property portfolio.

For a thorough assessment of BTAI stock, go to TipRanks’ Stock Analysis page.